Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.

× No keyword cloud information.

39 in total

1. Chemotherapy characteristics are important predictors of primary prophylactic CSF administration in older patients with breast cancer.

Authors: Suja S Rajan; Gary H Lyman; William R Carpenter; Sally C Stearns
Journal: Breast Cancer Res Treat Date: 2010-10-26 Impact factor: 4.872

2. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Authors: M S Aapro; J Bohlius; D A Cameron; Lissandra Dal Lago; J Peter Donnelly; N Kearney; G H Lyman; R Pettengell; V C Tjan-Heijnen; J Walewski; Damien C Weber; C Zielinski
Journal: Eur J Cancer Date: 2010-11-20 Impact factor: 9.162

3. Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Authors: Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Solomon B Makgoeng; Nadia Howlader; Jane C Weeks
Journal: J Natl Cancer Inst Date: 2011-06-13 Impact factor: 13.506

Review 4. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

Authors: Gary H Lyman; Jessica Malone Kleiner
Journal: Cancer Treat Res Date: 2011

Review 5. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.

Authors: Gary H Lyman; David C Dale; Debra A Wolff; Eva Culakova; Marek S Poniewierski; Nicole M Kuderer; Jeffrey Crawford
Journal: J Clin Oncol Date: 2010-04-12 Impact factor: 44.544

6. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America.

Authors: Alison G Freifeld; Eric J Bow; Kent A Sepkowitz; Michael J Boeckh; James I Ito; Craig A Mullen; Issam I Raad; Kenneth V Rolston; Jo-Anne H Young; John R Wingard
Journal: Clin Infect Dis Date: 2011-01-04 Impact factor: 9.079

7. Individualized guidelines: the potential for increasing quality and reducing costs.

Authors: David M Eddy; Joshua Adler; Bradley Patterson; Don Lucas; Kurt A Smith; Macdonald Morris
Journal: Ann Intern Med Date: 2011-05-03 Impact factor: 25.391

8. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.

Authors: Gary H Lyman; Nicole M Kuderer; Jeffrey Crawford; Debra A Wolff; Eva Culakova; Marek S Poniewierski; David C Dale
Journal: Cancer Date: 2010-11-29 Impact factor: 6.860

9. Risk of mortality in patients with cancer who experience febrile neutropenia.

Authors: Gary H Lyman; Shannon L Michels; Matthew W Reynolds; Rich Barron; Karen Smoyer Tomic; Jingbo Yu
Journal: Cancer Date: 2010-08-16 Impact factor: 6.860

10. Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy.

Authors: Scott D Ramsey; Zhimei Liu; Rob Boer; Sean D Sullivan; Jennifer Malin; Quan V Doan; Robert W Dubois; Gary H Lyman
Journal: Value Health Date: 2008-07-31 Impact factor: 5.725

13 in total

1. Re: personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy.

Authors: Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Jane C Weeks
Journal: J Natl Cancer Inst Date: 2011-10-28 Impact factor: 13.506

Review 2. A way forward on the medically appropriate use of white cell growth factors.

Authors: Thomas J Smith; Bruce E Hillner
Journal: J Clin Oncol Date: 2012-02-27 Impact factor: 44.544

3. Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy.

Authors: Abolfazl Razzaghdoust; Bahram Mofid; Maryam Moghadam
Journal: Support Care Cancer Date: 2018-05-07 Impact factor: 3.603

4. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.

Authors: Derek Weycker; Xiaoyan Li; Spiros Tzivelekis; Mark Atwood; Jacob Garcia; Yanli Li; Maureen Reiner; Gary H Lyman
Journal: Support Care Cancer Date: 2016-10-12 Impact factor: 3.603

5. A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.

Authors: Aasthaa Bansal; Sean D Sullivan; Dawn L Hershman; Gary H Lyman; William E Barlow; Jeannine S McCune; Scott D Ramsey
Journal: J Comp Eff Res Date: 2017-07-07 Impact factor: 1.744

6. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.

Authors: Hartmut Link; J Nietsch; M Kerkmann; P Ortner
Journal: Support Care Cancer Date: 2015-06-17 Impact factor: 3.603

Review 7. Mitigating acute chemotherapy-associated adverse events in patients with cancer.

Authors: Nicole M Kuderer; Aakash Desai; Maryam B Lustberg; Gary H Lyman
Journal: Nat Rev Clin Oncol Date: 2022-10-11 Impact factor: 65.011

8. Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?

Authors: Gary H Lyman; David C Dale; Jason C Legg; Esteban Abella; Phuong Khanh Morrow; Sadie Whittaker; Jeffrey Crawford
Journal: Cancer Med Date: 2015-03-23 Impact factor: 4.452

9. Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia.

Authors: Alper Sevinç; Metin Özkan; Ahmet Özet; Faysal Dane; Berna Öksüzoğlu; Abdurrahman Işıkdoğan; Feyyaz Özdemir; Doğan Uncu; Mahmut Gümüş; Türkkan Evrensel; Arzu Yaren; Oğuz Kara; Salim Başol Tekin
Journal: Onco Targets Ther Date: 2018-01-18 Impact factor: 4.147

10. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.

Authors: Derek Weycker; Xiaoyan Li; Rich Barron; Yanli Li; Maureen Reiner; Alex Kartashov; Jacqueline Figueredo; Spiros Tzivelekis; Jacob Garcia
Journal: Support Care Cancer Date: 2015-12-15 Impact factor: 3.603